Department of Psychiatry
  • Wstęp EN
  • Ogród EN

Clinical Study - ketamine treatment in depressive disorders


Dear Sir or Madam,

We have the opportunity to offer you ketamine treatment as part of a clinical trial. Until now, Ketamine has been used as an anesthetic, but it also turned out to have properties that quickly reduce depression symptoms.

If you are between 18 and 65 years old and have been diagnosed with depression, the symptoms of which are currently becoming more severe and your treatment has not improved (inadequate response to at least 2 antidepressants administered for a sufficient time and in a sufficient dose). You have no other psychiatric disorders (mental retardation, neurotic disorders, personality disorders) and you do not suffer from serious somatic diseases (liver, kidney or bronchial asthma).

The condition for reporting is information from your psychiatrist about the diagnosis you are being treated for and the current antidepressant treatment (medications, doses, duration of treatment).

Participation in the study will be associated with your consent for a 14-day hospitalization period in our clinical ward to monitor the safety of your treatment.

Feel free to contact us at 71 784 16 10 (PZP Kliniki Psychiatrii) after prior sending documentation (subject of ketamine e-mail) to This email address is being protected from spambots. You need JavaScript enabled to view it..

 

 

Clinical Study - ketamine treatment in bipolar disorder


Dear Sir or Madam,

We have the opportunity to offer you ketamine treatment as part of a clinical trial. Until now, Ketamine has been used as an anesthetic, but it also turned out to have properties that quickly reduce depression symptoms.

If you are aged 18-65 and have a bipolar disorder and are currently suffering from depression, the symptoms of which are currently becoming more severe, the current treatment has not improved (inadequate response to at least 2 mood stabilizers given for a sufficient time and in a sufficient dose) ). You have no other psychiatric disorders (mental retardation, neurotic disorders, personality disorders) and you do not suffer from serious somatic diseases (liver, kidney or bronchial asthma).

The condition for reporting is information from your psychiatrist about the diagnosis you are being treated for and the treatment of bipolar disorder to date (medications, doses, duration of treatment).

Participation in the study will be associated with your consent for a 14-day hospitalization period in our clinical ward to monitor the safety of your treatment.

Feel free to contact us at 71 784 16 10 (PZP Kliniki Psychiatrii) after prior sending documentation (subject of ketamine e-mail) to This email address is being protected from spambots. You need JavaScript enabled to view it..